Tesamorelin Therapy: Abdominal Visceral Fat Reduction
Tesamorelin therapy is a FDA-approved growth hormone-releasing hormone (GHRH) analog with Phase 3 clinical evidence for targeted visceral fat reduction — making it the most regulatory-credentialed peptide in the body composition research space. This guide reviews the mechanism, published trial data, off-label applications, and key sourcing considerations for researchers.
Shop Research Peptides →
What Is Tesamorelin Therapy?
Tesamorelin is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH) that mimics the body’s natural signal to the pituitary gland, stimulating the release of growth hormone through physiological pathways. Unlike exogenous human growth hormone, tesamorelin acts upstream — prompting the pituitary gland to produce its own growth hormone pulse rather than replacing it directly. Clinical research published in PubMed Central (2010) confirms that tesamorelin preserves the pulsatile release pattern of natural growth hormone, a key distinction from direct GH administration.
The compound was developed under the brand name Egrifta and received FDA approval in 2010 for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy — the only FDA-approved indication for any peptide in this category. Compounded tesamorelin is also available through licensed compounding pharmacies for off-label research and clinical applications, making it one of the most investigated peptide compounds in metabolic research.
The significance of tesamorelin therapy in current research extends well beyond its original lipodystrophy indication. Investigators have studied the compound’s downstream effects on visceral adipose tissue, insulin sensitivity, lipid profiles, and cognitive function — building a broader evidence base that informs both clinical and preclinical research protocols. Emerging studies are now exploring the tesamorelin dosage for fat loss, focusing on optimal administration strategies to enhance its efficacy. Researchers are particularly interested in its potential to influence body composition and metabolic health in diverse populations. As this body of research grows, it may pave the way for novel therapeutic approaches in weight management and obesity treatment.
Mechanism of Action: How Tesamorelin Works
Tesamorelin acts by binding to GHRH receptors on somatotroph cells of the anterior pituitary gland, triggering a downstream cascade that results in the release of endogenous growth hormone. This mechanism preserves the body’s natural feedback regulation — the hypothalamic-pituitary-somatotroph axis — unlike direct growth hormone administration, which bypasses these controls entirely.
GHRH Analog Structure and Receptor Binding
Tesamorelin is a synthetic analog of growth hormone-releasing hormone that includes a trans-3-hexenoic acid modification at the N-terminus. This structural addition protects the molecule from enzymatic degradation by dipeptidyl peptidase IV (DPP-IV), significantly extending its half-life and bioavailability compared to native GHRH. The result is a more sustained receptor engagement with the pituitary gland than the endogenous peptide achieves, driving a more reproducible growth hormone release pattern in research models.
Downstream Effects on Growth Hormone and IGF-1
Once tesamorelin stimulates the pituitary gland, the resulting growth hormone pulse drives hepatic production of insulin-like growth factor 1 (IGF-1). Both GH and IGF-1 act on adipose tissue — particularly visceral adipose tissue — to promote lipolysis, the breakdown of stored fat into free fatty acids. This mechanism is the primary driver of tesamorelin’s documented effects on abdominal fat reduction and body composition in published clinical trials.
Importantly, tesamorelin increases IGF-1 within a physiological range rather than producing supraphysiological spikes. Published research in PMC (2010) noted that IGF-1 levels in treated subjects rose from baseline but remained within the normal reference range for age-matched adults, supporting the relative safety profile observed in trials.
Selectivity for Visceral Adipose Tissue
A defining feature of tesamorelin therapy in research is its apparent selectivity for visceral adipose tissue (VAT) over subcutaneous fat compartments. Visceral fat — the metabolically active fat stored around internal organs — is more sensitive to growth hormone-driven lipolysis than subcutaneous fat stores. Clinical trial data consistently show preferential reductions in VAT measured by CT scan, with comparatively modest changes in limb fat, a distinction that makes tesamorelin uniquely relevant to metabolic disease research. Tesamorelin benefits for fat loss extend beyond mere weight reduction, as it actively promotes a healthier body composition. By targeting visceral fat, tesamorelin not only aids in achieving fat loss goals but also significantly influences metabolic health markers. This unique action makes it an intriguing option for those looking to improve overall well-being while addressing obesity-related risks.
Research Insight: Pulsatile GH Preservation
- Tesamorelin maintains the natural pulsatile growth hormone release pattern, unlike direct GH injection
- Pulsatile secretion is associated with more favorable metabolic profiles in endocrine research models
- This distinction is frequently cited as the mechanistic basis for tesamorelin’s lipodystrophy efficacy
FDA Approval & Phase 3 Clinical Trial Data for Tesamorelin Therapy
Tesamorelin therapy holds the strongest regulatory credential of any peptide in the body composition space. Its FDA approval rests on two pivotal Phase 3 randomized controlled trials — the most rigorous evidence standard in clinical research — establishing it as the benchmark for evidence-based visceral fat reduction research.
LIPO1 and LIPO2 Phase 3 Trials
The pivotal trials, known as LIPO1 and LIPO2, enrolled HIV-infected adults with excess abdominal fat resulting from antiretroviral-associated lipodystrophy. Participants received daily subcutaneous injections of 2 mg tesamorelin or placebo for 26 weeks. The New England Journal of Medicine trial publication (2010) reported that tesamorelin-treated subjects experienced statistically significant reductions in visceral adipose tissue compared to placebo, with CT-measured VAT declining by approximately 15% from baseline in the active arm.
Beyond the primary VAT endpoint, trial data documented improvements in waist circumference, triglyceride levels, and patient-reported abdominal appearance — outcomes aligned with broader metabolic health profiles. Secondary analyses confirmed that changes in abdominal fat were accompanied by favorable trends in lipid metabolism without significant adverse effects on glucose homeostasis at the studied dose.
Discontinuation and Rebound Effect
One clinically significant finding from both Phase 3 trials was the observation that visceral fat and metabolic improvements were not sustained after tesamorelin was discontinued. Subjects who ceased treatment showed a return toward baseline VAT levels within weeks, suggesting that the compound’s effects are dependent on continued administration rather than producing durable structural changes. This finding is critical for researchers designing study protocols and assessing whether tesamorelin’s impact is maintained over extended periods.
FDA Approval for Lipodystrophy
Based on the Phase 3 data, the FDA approved Egrifta (tesamorelin for injection) in November 2010 for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. This approval represented the first and only FDA-sanctioned indication for a GHRH analog for body composition modification, distinguishing tesamorelin from all other peptides in this research category. The regulatory framework established through the Egrifta approval has since informed compounded tesamorelin prescriptions for off-label applications under physician supervision.
Metabolic Effects & Body Composition Research
Beyond its documented impact on visceral adipose tissue volume, tesamorelin therapy has been studied for a range of secondary metabolic effects. Research consistently positions this compound as metabolically active across multiple pathways relevant to body composition, lipid metabolism, and insulin sensitivity. Further investigations into tesamorelin effects on visceral fat have revealed potential benefits in improving cardiovascular health markers. In addition to reducing visceral fat, patients may experience enhanced glucose metabolism, contributing to better overall metabolic control. These findings suggest that tesamorelin may offer a multifaceted approach to managing obesity-related health risks.
Effects on Triglycerides and Lipid Profiles
Multiple Phase 3 and extension trial analyses documented reductions in fasting triglyceride levels among subjects treated with tesamorelin. Elevated triglycerides are a hallmark of visceral adiposity and metabolic disease, and their reduction in parallel with VAT decline supports the hypothesis that tesamorelin therapy addresses the underlying metabolic dysfunction associated with excess abdominal fat accumulation. These lipid improvements have been noted as independent secondary outcomes in several peer-reviewed analyses, though the clinical magnitude varies across sub-populations.
Insulin Sensitivity Considerations
Insulin resistance is a well-documented consequence of excess visceral fat. Researchers have examined whether tesamorelin’s VAT-reducing effects translate to improved insulin sensitivity at the metabolic level. The evidence is nuanced: while some subjects showed favorable trends in glucose metabolism, a subset experienced modest increases in fasting glucose, attributable to the direct effects of elevated growth hormone on insulin signaling. This dual metabolic effect — improved lipid profiles alongside potential glucose challenges — is one of the primary research considerations when evaluating tesamorelin’s overall metabolic effects.
Why This Matters
Understanding the balance between triglyceride reduction and insulin resistance risk is central to interpreting the downstream effects of tesamorelin in both HIV-associated lipodystrophy and general metabolic research contexts. Researchers designing studies should include both lipid and glucose monitoring endpoints to capture the full metabolic profile.
Body Composition: Lean Muscle and Fat Distribution
Tesamorelin’s increases in growth hormone and IGF-1 have raised research interest in potential effects on lean muscle mass and overall body composition beyond visceral fat. While the primary published evidence base focuses on visceral adipose tissue reduction, some studies have assessed whether concomitant changes in lean body mass occur. Results from Phase 3 extension data suggest that lean muscle preservation — rather than significant mass gain — is the typical pattern at standard doses, consistent with the compound’s positioning as a metabolic modifier rather than an anabolic agent.
- Significant visceral fat reductions measured by CT at 26 weeks (LIPO1/LIPO2)
- Favorable triglyceride reductions observed as secondary endpoints
- Modest IGF-1 increases remaining within normal physiological reference ranges
- Potential for mild fasting glucose elevation — requires co-monitoring in protocols
- Lean muscle mass broadly preserved at standard 2 mg/day dosing
- Effects reverse upon discontinuation — VAT returns toward baseline within weeks
Off-Label Research Applications of Tesamorelin
While tesamorelin’s FDA-approved indication is specific to HIV-associated lipodystrophy, its documented mechanism of action has prompted substantial off-label research into broader applications — particularly in non-HIV populations with excess visceral fat and metabolic dysfunction.
Non-HIV Abdominal Fat Reduction Research
Several investigator-initiated studies have assessed whether tesamorelin’s body composition effects extend to non-HIV adults with excess abdominal fat accumulation. A key question in off-label research has been whether the mechanism — pituitary-mediated GH release → IGF-1 elevation → visceral lipolysis — operates similarly regardless of the etiology of the excess fat. Preliminary data from non-HIV cohorts suggest comparable VAT reduction patterns, though effect sizes may differ in populations without the GH deficiency commonly associated with antiretroviral therapy.
Cognitive Research and Alzheimer’s Disease
Emerging research has explored tesamorelin’s potential effects on cognitive function, particularly in older adults with mild cognitive impairment. Growth hormone and IGF-1 have established roles in neuroplasticity and synaptic function, and their decline with aging is associated with cognitive changes. A 2012 randomized trial published in JAMA Neurology (PMID: 22810177) examined whether tesamorelin could improve cognitive markers in this population — one of the few rigorous investigations into a peptide’s cognitive research applications.
Key Research Finding
The cognitive research line represents one of the most scientifically significant expansions of tesamorelin’s evidence base beyond its original metabolic indication. While findings are preliminary and not grounds for clinical application outside of research protocols, the mechanistic rationale is sound: GH/IGF-1 signaling intersects with known pathways implicated in age-related cognitive decline.
Compounded Tesamorelin for Off-Label Use
Compounded tesamorelin is prepared by licensed compounding pharmacies and may be prescribed off-label by physicians for research and clinical investigation in non-approved populations. Unlike the branded Egrifta formulation, compounded versions are not reviewed by the FDA for efficacy or safety in off-label applications — a distinction relevant to both prescribers and research teams evaluating peptide sources. For strictly laboratory research use, researchers source tesamorelin through verified research-grade suppliers with documented purity and sterility certificates.
Off-Label Research Tip
- Off-label research protocols should include VAT measurement by CT or DXA for quantitative body composition endpoints
- Researchers should include metabolic panels monitoring fasting glucose, insulin, and triglycerides given tesamorelin’s dual metabolic effects
- Compounded tesamorelin purity documentation (HPLC, COA) is essential for protocol reproducibility
⚠️ 5 Important Research Considerations for Tesamorelin Therapy
Researchers approaching tesamorelin studies must account for the following limitations and variables to ensure valid, reproducible outcomes.
- Reversibility of effects: VAT reductions demonstrated in clinical trials reversed substantially upon tesamorelin discontinuation, meaning the compound does not produce durable fat loss without continued administration. Study designs must account for this in endpoint selection and follow-up timing.
- Glucose metabolism perturbation: Tesamorelin’s stimulation of growth hormone can produce modest insulin resistance in some subjects. Research protocols that do not monitor fasting glucose and HbA1c alongside VAT endpoints may miss an important adverse signal.
- Population-specific data gaps: The strongest clinical evidence comes from HIV-infected adults with lipodystrophy. Off-label applications in non-HIV populations rely on extrapolation and smaller investigator-initiated studies — a significant evidence gap that limits generalizability.
- IGF-1 monitoring requirements: Tesamorelin increases circulating IGF-1 as part of its mechanism. Elevated IGF-1 is associated with certain adverse outcomes in some populations; researchers should define IGF-1 monitoring checkpoints in study protocols.
- Purity and source variability: Compounded and research-grade tesamorelin peptide preparations vary considerably in purity, endotoxin levels, and sterility — directly affecting the validity of in vitro and in vivo findings. Only verified, COA-documented sources produce consistent research outcomes.
Issue: Undocumented purity → Research Impact: Confounded dose-response data and unreproducible findings across studies.
Issue: Missing glucose monitoring → Research Impact: Failure to detect metabolic perturbation as a co-primary outcome.
Issue: Extrapolating HIV data to general population → Research Impact: Overestimating expected effect sizes in off-label cohorts.
Sourcing research-grade peptides with verified purity documentation reduces these variables significantly. View Phoenix Peptide Labs quality standards →
✅ What the Research Shows About Tesamorelin Therapy
The body of evidence behind tesamorelin is grounded in Phase 3 RCTs, regulatory review, and independent investigator-initiated research — representing a uniquely robust evidence base for a peptide compound.
Research backing: The Phase 3 LIPO1 and LIPO2 trials, published in the New England Journal of Medicine (2010), remain the primary evidence pillars. Subsequent extension data and off-label investigations have expanded the evidence base without contradicting core Phase 3 findings.
Researchers who apply rigorous monitoring frameworks — including CT-measured VAT endpoints, metabolic panels, and sourcing from purity-verified suppliers — consistently report more reproducible and interpretable data across tesamorelin studies.
How to Evaluate Tesamorelin Therapy Research: Key Factors to Consider
Quick Answer: Evaluating tesamorelin research requires assessing evidence quality (Phase 3 RCT vs. off-label pilot studies), monitoring framework design (VAT imaging, metabolic panels, IGF-1), peptide source purity (HPLC documentation, COA), and population-specific generalizability. The compound’s FDA approval for lipodystrophy provides an unusually strong evidence anchor, but researchers must account for reversal of effects upon discontinuation and glucose monitoring requirements when designing or interpreting studies.
Interpreting tesamorelin research requires more than reviewing efficacy endpoints. The compound’s dual metabolic effects, population-specific evidence base, and source variability all influence how findings should be weighted and applied.
Factor 1: Evidence Tier — Phase 3 vs. Off-Label Pilot Data
The foundation of tesamorelin’s evidence base is Phase 3 randomized controlled trial data, which provides the highest confidence in reported effects. Researchers should clearly distinguish between findings from these pivotal trials (HIV lipodystrophy population, N > 400 per trial) and smaller off-label investigations in non-HIV populations. Effect sizes and statistical confidence intervals differ markedly between these evidence tiers.
Off-label research exploring tesamorelin in general metabolic disease, non-HIV abdominal fat accumulation, or cognitive endpoints warrants greater caution in interpretation. These studies frequently lack the statistical power of Phase 3 designs and may not control for confounders present in non-lipodystrophy populations.
Factor 2: Endpoint Selection — VAT Measurement and Metabolic Panels
CT scan measurement of visceral adipose tissue volume is the gold standard endpoint used in Phase 3 tesamorelin research. Studies relying on waist circumference or scale weight as proxies for VAT changes introduce significant measurement imprecision. Waist circumference can decline modestly even without meaningful VAT reduction, making CT or DXA-based body composition measurement a requirement for rigorous body composition and metabolic research protocols.
Secondary metabolic endpoints — fasting triglycerides, LDL, fasting glucose, and HbA1c — should be co-primary in any research design given tesamorelin’s known effects on both lipid and glucose metabolism.
Factor 3: Peptide Source Purity and Certificate of Analysis
Research reproducibility depends critically on compound purity. Tesamorelin preparations with undocumented purity levels introduce dose variability and endotoxin contamination risk — both of which confound in vitro and in vivo outcomes. Research-grade tesamorelin peptide should carry HPLC purity documentation (typically ≥98%), mass spectrometry confirmation, and sterility testing certificates from independent third-party laboratories.
The distinction between branded Egrifta (FDA-reviewed manufacturing), licensed compounded tesamorelin, and research-grade peptide preparations is material for regulatory compliance and experimental validity. Researchers must select the appropriate source tier for their specific research context.
Ready to source research-grade tesamorelin? Shop Phoenix Peptide Labs’ verified peptide catalog →
Factor 4: Duration and Discontinuation Planning
Tesamorelin’s documented reversal of effects upon cessation is a critical study design variable. Researchers assessing longer-term metabolic outcomes must build discontinuation monitoring windows into their protocols. Extension trial data show that VAT levels begin returning toward baseline within 12–16 weeks of stopping treatment, which has direct implications for follow-up endpoint timing.
Studies that do not include a post-treatment follow-up period risk underestimating the impermanence of tesamorelin’s body composition effects — a finding that is as informative for the research as the acute treatment phase itself.
Factor 5: Population Generalizability
The HIV-infected adult population studied in Phase 3 trials exhibits a specific GH deficiency profile driven by antiretroviral therapy — a mechanistic context that may not replicate in general obesity or age-related metabolic disease populations. Researchers extrapolating from LIPO1/LIPO2 data to non-HIV populations should account for baseline growth hormone secretion differences and the distinct etiology of visceral fat accumulation in those cohorts.
Factor 6: Adverse Effect Monitoring in Research Protocols
Tesamorelin injection may cause site reactions (redness, pruritus, induration) at the injection site, fluid retention, and potential glucose metabolism changes. Systematic adverse event monitoring is required in any clinical research protocol. Injection site reactions were the most common adverse event documented in Phase 3 trials and should be captured as a safety endpoint rather than an incidental finding.
Tesamorelin vs. Other GHRH Analogs: Research Comparison
Tesamorelin occupies a unique position among GHRH analog peptides due to its FDA approval status, Phase 3 evidence base, and documented visceral fat selectivity. The following comparison situates it within the broader research landscape of growth hormone-related peptide compounds.
| Compound | Class | FDA Status | Primary Research Use | Visceral Fat Evidence | Evidence Tier |
|---|---|---|---|---|---|
| Tesamorelin | GHRH Analog | FDA-Approved (Egrifta) | Visceral fat / lipodystrophy / metabolic | Phase 3 RCT (~15% VAT reduction) | Highest (Phase 3 RCT) |
| Sermorelin | GHRH Analog (1–29 fragment) | Compounded / Off-label | GH stimulation / anti-aging research | Limited — indirect via GH/IGF-1 | Moderate (Phase 2 / case series) |
| CJC-1295 | GHRH Analog (modified) | Research Use Only | GH pulse amplification / body composition | Preclinical / limited human data | Low (Phase 1–2 only) |
| Ipamorelin | GH Secretagogue (GHRP) | Research Use Only | GH release / lean mass / metabolic | Preclinical only | Low (preclinical) |
| GH (Somatropin) | Recombinant Human GH | FDA-Approved (multiple) | GH deficiency / pediatric / lipodystrophy | Established (bypasses pituitary axis) | High (multiple Phase 3) |
Data compiled from FDA drug approvals, PubMed-indexed clinical trials, and published review literature. Last reviewed April 2026.
Who Uses Tesamorelin in Research?
Tesamorelin research spans a wide range of investigators — from academic endocrinologists working in HIV medicine to independent labs exploring off-label metabolic applications.
The Endocrinology Researcher
An academic investigator studying visceral fat metabolism and GH axis dysfunction in lipodystrophy or metabolic disease populations. They require Phase 3-level evidence anchors and rigorous COA documentation for institutional compliance.
The Independent Lab Scientist
A preclinical researcher investigating GHRH analog mechanisms in animal models, evaluating tesamorelin’s effects on visceral adipose tissue gene expression or metabolic biomarkers. Purity and lot-to-lot consistency are critical for reproducible data.
The Clinical Protocol Designer
A physician-researcher or clinical coordinator designing an off-label tesamorelin study in a non-HIV metabolic disease population, navigating the gap between the lipodystrophy evidence base and general population applications.
Frequently Asked Questions
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to release natural growth hormone. It binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering a GH pulse that drives IGF-1 production and, downstream, lipolysis in visceral adipose tissue. Unlike direct GH administration, tesamorelin preserves the body’s own feedback regulation of GH secretion. Published research in PMC (2010) confirms this pulsatile mechanism as central to tesamorelin’s efficacy profile. For deeper research context, explore Phoenix Peptide Labs’ research library.
Phase 3 clinical trials (LIPO1 and LIPO2) — the regulatory basis for FDA approval — demonstrated approximately 15% reduction in visceral adipose tissue at 26 weeks compared to placebo in HIV-infected adults with lipodystrophy. Results were published in the New England Journal of Medicine (2010). Secondary endpoints showed improvements in triglycerides and waist circumference. Critically, effects reversed after discontinuation of treatment, indicating that sustained results require continued administration. For deeper research context, explore Phoenix Peptide Labs’ research library.
Research-grade tesamorelin peptide should meet ≥98% purity by HPLC analysis, with mass spectrometry confirmation of molecular identity and independent third-party certificate of analysis (COA). Endotoxin testing and sterility documentation are additional requirements for in vivo research. Preparations lacking third-party COA introduce dose variability and contamination risk that directly confound experimental outcomes. For sourcing questions or documentation requests, contact Phoenix Peptide Labs directly.
Phase 3 trial data identified injection site reactions (redness, itching, swelling) as the most common adverse events. Fluid retention was also reported in a subset of subjects. A clinically meaningful finding was modest elevation in fasting glucose in some participants, consistent with GH-mediated insulin resistance — making glucose monitoring a required safety checkpoint in research protocols. IGF-1 elevations were observed but remained within normal reference ranges at the studied 2 mg/day dose. For sourcing questions or documentation requests, contact Phoenix Peptide Labs directly.
Need technical specifications or purity documentation? Contact Phoenix Peptide Labs directly →
Egrifta is the FDA-approved branded formulation of tesamorelin manufactured under GMP standards and reviewed by the FDA for safety, efficacy, and manufacturing quality in its approved indication. Compounded tesamorelin is prepared by licensed compounding pharmacies for off-label use under physician prescription — it is not FDA-reviewed for off-label applications. Research-grade tesamorelin peptide is sourced through verified research chemical suppliers for laboratory and preclinical use only, and is not intended for human therapeutic administration. For sourcing questions or documentation requests, contact Phoenix Peptide Labs directly.
The primary limitation is population specificity: the strongest evidence comes exclusively from HIV-infected adults with antiretroviral-associated lipodystrophy, limiting direct generalizability to other populations. Additional limitations include the reversal of effects upon discontinuation, modest evidence for long-term safety beyond 52 weeks, limited off-label data in non-HIV metabolic disease populations, and variability in compounded/research-grade peptide purity across suppliers. Off-label cognitive and aging research is preliminary and requires replication in larger trials. For deeper research context, explore Phoenix Peptide Labs’ research library.
Tesamorelin (Egrifta) is FDA-approved exclusively for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. No other human therapeutic indication has received FDA approval. All other applications — including general obesity, off-label metabolic disease, and cognitive research — are investigational and conducted under research protocols only. Research-grade tesamorelin peptide sold by suppliers like Phoenix Peptide Labs is strictly for laboratory and research use, and is not approved, intended, or sold for human therapeutic administration. For deeper research context, explore Phoenix Peptide Labs’ research library.
Tesamorelin and ipamorelin both stimulate growth hormone release but through distinct mechanisms: tesamorelin is a GHRH analog acting on the GHRH receptor, while ipamorelin is a ghrelin mimetic acting on the growth hormone secretagogue receptor (GHSR). Tesamorelin has far superior clinical evidence — Phase 3 RCT data and FDA approval versus preclinical and small Phase 1/2 data for ipamorelin. Tesamorelin’s selectivity for visceral fat has been directly quantified by CT in large trials; comparable data do not exist for ipamorelin. Researchers requiring the strongest evidence anchor in body composition studies should prioritize tesamorelin protocols. For sourcing questions or documentation requests, contact Phoenix Peptide Labs directly.
⚗️ Research Use Disclaimer
All content on this page is intended for informational and research purposes only. The compounds discussed are not approved by the FDA for human therapeutic use outside of their specifically approved indications. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a licensed medical professional before making any health-related decisions. Phoenix Peptide Labs products are sold strictly for laboratory and research use. Researchers are responsible for compliance with all applicable local, state, and federal regulations governing the use of research compounds.